

Special Issue

Lipid-Based Formulations for Therapy of Vector-Borne Protozoan Diseases

Message from the Guest Editor

Vector-borne protozoan diseases represent a serious public health problem, especially in the tropics where poverty, together with vector-favorable climates, prevails. Diseases caused by Plasmodia (malaria), and three major trypanosomatid diseases (leishmaniasis, African Human Trypanosomiasis (HAT) and Chagas disease) are among the most prevalent and severe human vector-borne protozoan infections. There is urgent need for new more effective drugs and therapeutic strategies for these diseases. This Special Issue seeks to present a collection of innovative studies describing recent advances in the development of lipid-based drug formulations to improve the therapy of vector-borne protozoan infections. Special attention is given to works that explore alternative administration routes, immunochemotherapy strategies and address major challenges in current drug development, such as drug delivery across biological barriers, effective drug targeting, as well as the formulation of large molecules.

Guest Editor

Prof. Dr. Frédéric Frézard

Department Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Minas Gerais, Brazil

Deadline for manuscript submissions

closed (10 May 2023)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/113866

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).